
Zhenlin Ju

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1195453/publications.pdf Version: 2024-02-01



ΖΗΕΝΙΙΝ ΙΙΙ

#	Article	IF	CITATIONS
1	Gene signature associated with resistance to fluvastatin chemoprevention for breast cancer. BMC Cancer, 2022, 22, 282.	2.6	3
2	Frequent post-operative monitoring of colorectal cancer using individualised ctDNA validated by multiregional molecular profiling. British Journal of Cancer, 2021, 124, 1556-1565.	6.4	9
3	Clinical relevance of TP53 hotspot mutations in high-grade serous ovarian cancers. British Journal of Cancer, 2020, 122, 405-412.	6.4	53
4	Analysis of mutational and proteomic heterogeneity of gastric cancer suggests an effective pipeline to monitor post-treatment tumor burden using circulating tumor DNA. PLoS ONE, 2020, 15, e0239966.	2.5	4
5	Melanoma Evolves Complete Immunotherapy Resistance through the Acquisition of a Hypermetabolic Phenotype. Cancer Immunology Research, 2020, 8, 1365-1380.	3.4	37
6	Large-Scale Characterization of Drug Responses of Clinically Relevant Proteins in Cancer Cell Lines. Cancer Cell, 2020, 38, 829-843.e4.	16.8	40
7	Immuno-genomic landscape of osteosarcoma. Nature Communications, 2020, 11, 1008.	12.8	143
8	Development of prediction models for lymph node metastasis in endometrioid endometrial carcinoma. British Journal of Cancer, 2020, 122, 1014-1022.	6.4	9
9	Inhibition of the ATM/Chk2 axis promotes cGAS/STING signaling in ARID1A-deficient tumors. Journal of Clinical Investigation, 2020, 130, 5951-5966.	8.2	72
10	Title is missing!. , 2020, 15, e0239966.		0
11	Title is missing!. , 2020, 15, e0239966.		0
12	Title is missing!. , 2020, 15, e0239966.		0
13	Title is missing!. , 2020, 15, e0239966.		0
14	Safety lead-in of the MEK inhibitor trametinib in combination with GSK2141795, an AKT inhibitor, in patients with recurrent endometrial cancer: An NRG Oncology/GOG study. Gynecologic Oncology, 2019, 155, 420-428.	1.4	28
15	Adaptive responses in a PARP inhibitor window of opportunity trial illustrate limited functional interlesional heterogeneity and potential combination therapy options. Oncotarget, 2019, 10, 3533-3546.	1.8	19
16	Sequential Therapy with PARP and WEE1 Inhibitors Minimizes Toxicity while Maintaining Efficacy. Cancer Cell, 2019, 35, 851-867.e7.	16.8	156
17	PARPi Triggers the STING-Dependent Immune Response and Enhances the Therapeutic Efficacy of Immune Checkpoint Blockade Independent of BRCAness. Cancer Research, 2019, 79, 311-319.	0.9	404
18	BRD4 Inhibition Is Synthetic Lethal with PARP Inhibitors through the Induction of Homologous Recombination Deficiency. Cancer Cell, 2018, 33, 401-416.e8.	16.8	215

Zhenlin Ju

#	Article	IF	CITATIONS
19	Systematic Functional Annotation of Somatic Mutations in Cancer. Cancer Cell, 2018, 33, 450-462.e10.	16.8	213
20	Neomorphic PDGFRA extracellular domain driver mutations are resistant to PDGFRA targeted therapies. Nature Communications, 2018, 9, 4583.	12.8	44
21	A Pan-Cancer Analysis Reveals High-Frequency Genetic Alterations in Mediators of Signaling by the TGF-β Superfamily. Cell Systems, 2018, 7, 422-437.e7.	6.2	134
22	Essential roles of mitochondrial biogenesis regulator Nrf1 in retinal development and homeostasis. Molecular Neurodegeneration, 2018, 13, 56.	10.8	54
23	ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nature Medicine, 2018, 24, 556-562.	30.7	372
24	YAP/TAZ-Mediated Upregulation of GAB2 Leads to Increased Sensitivity to Growth Factor–Induced Activation of the PI3K Pathway. Cancer Research, 2017, 77, 1637-1648.	0.9	47
25	Characterization of Human Cancer Cell Lines by Reverse-phase Protein Arrays. Cancer Cell, 2017, 31, 225-239.	16.8	190
26	A murine preclinical syngeneic transplantation model for breast cancer precision medicine. Science Advances, 2017, 3, e1600957.	10.3	10
27	Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in <i>RAS</i> mutant cancers. Science Translational Medicine, 2017, 9, .	12.4	174
28	Improved prediction of PARP inhibitor response and identification of synergizing agents through use of a novel gene expression signature generation algorithm. Npj Systems Biology and Applications, 2017, 3, 8.	3.0	55
29	DNA-Methyltransferase 1 Induces Dedifferentiation of Pancreatic Cancer Cells through Silencing of Krüppel-Like Factor 4 Expression. Clinical Cancer Research, 2017, 23, 5585-5597.	7.0	34
30	Proteomic profiling of endometrioid endometrial cancer reveals differential expression of hormone receptors and MAPK signaling proteins in obese versus non-obese patients. Oncotarget, 2017, 8, 106989-107001.	1.8	9
31	High Intratumoral Stromal Content Defines Reactive Breast Cancer as a Low-risk Breast Cancer Subtype. Clinical Cancer Research, 2016, 22, 5068-5078.	7.0	38
32	Proteomic Characterization of Head and Neck Cancer Patient–Derived Xenografts. Molecular Cancer Research, 2016, 14, 278-286.	3.4	48
33	ARID1A Deficiency Impairs the DNA Damage Checkpoint and Sensitizes Cells to PARP Inhibitors. Cancer Discovery, 2015, 5, 752-767.	9.4	361
34	PTEN loss is a contextâ€dependent outcome determinant in obese and nonâ€obese endometrioid endometrial cancer patients. Molecular Oncology, 2015, 9, 1694-1703.	4.6	47
35	Prognostic relevance of acquired uniparental disomy in serous ovarian cancer. Molecular Cancer, 2015, 14, 29.	19.2	15
36	The Genomic Landscape and Clinical Relevance of A-to-I RNA Editing in Human Cancers. Cancer Cell, 2015, 28, 515-528.	16.8	426

Zhenlin Ju

#	Article	IF	CITATIONS
37	Development of a robust classifier for quality control of reverse-phase protein arrays. Bioinformatics, 2015, 31, 912-918.	4.1	43
38	Naturally Occurring Neomorphic PIK3R1 Mutations Activate the MAPK Pathway, Dictating Therapeutic Response to MAPK Pathway Inhibitors. Cancer Cell, 2014, 26, 479-494.	16.8	73
39	A pan-cancer proteomic perspective on The Cancer Genome Atlas. Nature Communications, 2014, 5, 3887.	12.8	456
40	A Comprehensive Comparison of Normalization Methods for Loading Control and Variance Stabilization of Reverse-Phase Protein Array Data. Cancer Informatics, 2014, 13, CIN.S13329.	1.9	19
41	Whole-exome sequencing combined with functional genomics reveals novel candidate driver cancer genes in endometrial cancer. Genome Research, 2012, 22, 2120-2129.	5.5	206
42	An efficient procedure for protein extraction from formalin-fixed, paraffin-embedded tissues for reverse phase protein arrays. Proteome Science, 2012, 10, 56.	1.7	59